Introduction
============

More than 100 human papillomaviruses (HPVs) have been identified, among which approximately 20 types are known as high-risk or oncogenic types \[[@b1-crt-2016-013]\]. High-risk HPVs are the most important contributors to the development of cervical precancerous lesions and invasive carcinomas. The prevalence of cervical cancer varies remarkably in different countries; this is mainly related to the availability of cervical cancer screening programs \[[@b2-crt-2016-013]\]. In Korea, despite a decrease in cervical cancer incidence from 1999 to 2012 because of an organized screening program, it is still predicted to be the seventh most common female cancer with 3,100 new cases and the third most common cancer in women aged 15 to 34 in 2015 \[[@b3-crt-2016-013]-[@b5-crt-2016-013]\].

Persistent infection with high-risk HPVs is a primary risk factor for cervical carcinogenesis. Among the high-risk HPVs, HPV 16 and HPV 18 are the two most carcinogenic genotypes and current prophylactic vaccines against HPV 16/18 may prevent up to 70% of cervical cancers \[[@b6-crt-2016-013]\]. High-risk HPVs other than HPV 16/18 cause the remaining 25%-35% of cervical cancers \[[@b7-crt-2016-013]\]. Globally, the most common genotypes other than HPV 16/18, in descending order of frequency are: HPV 45, 31, 33, 52, 58, and 35 \[[@b8-crt-2016-013]\]. However, there is considerable geographical variation in the prevalence of these HPV types. The prevalence of other high-risk HPV types is higher in Asia, Africa, and South/Central America (30%-35%) than in Europe, Oceania, and North America (23%-26%) \[[@b7-crt-2016-013]\]. Clarification of the contributions of individual genotypes causing cervical carcinogenesis will be important in order to provide an estimate of the potential impact of prophylactic vaccines and cancer screening programs.

This is a prospective study in a Korean HPV cohort \[[@b9-crt-2016-013]\]. The aims of this study were first to evaluate the distributional proportions along the full spectrum of high-risk HPVs in a Korean HPV cohort, and second, to determine the natural progression of atypical squamous cells of unknown significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) with high-risk HPV infections other than HPV 16/18.

Materials and Methods
=====================

A Korean HPV cohort study was conducted between April 2010 and October 2014. The HPV cohort recruited women aged 20 to 60 who satisfied both criteria of HPV positivity and abnormal cervical cytology of either ASC-US or LSIL from five institutions nationwide. Exclusion criteria included any of the following: previous hysterectomy, history of cervical intraepithelial neoplasia (CIN) treated within 6 months, pregnancy, coexisting malignancies, and psychological diseases currently under treatment. The study was approved by the institutional review board and informed consent was obtained from each participant prior to the study.

Enrolled patients underwent cervical liquid-based cytology and HPV DNA testing every 6 months. Cytological progression was defined as the change to atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (HSIL), HSIL, and LSIL from ASC-US, or as the change to HSIL from LSIL. Regression was defined as the change to normal cytology or ASC-US from LSIL, or to normal cytology from ASC-US. The others were categorized as no change. Colposcopy-directed biopsies were performed in patients with cytologic results indicative of conditions worse than HSIL. Patients diagnosed as having a lesion classified as greater than CIN 2 by colposcopy-directed biopsy were terminated in this study. Cervical samples were collected using a Cervex-Brush (Rovers Medical Devices, Oss, Netherlands) from cervical os and SurePath liquid-based cytology (TriPath Imaging, Inc., Burlington, NC) was used during the follow-up examinations. Cheil General Hospital served as a central laboratory for cytological diagnoses according to the 2001 Bethesda reporting system \[[@b10-crt-2016-013]\], and HPV genotyping testing during the follow-up examinations. HPV genotyping was performed using a DNA microarray technique with a Cheil HPV DNA Chip Kit (Cheil General Hospital, Seoul, Korea), based on a polymerase chain reaction method. Briefly, post-amplification SYBR Green reverse transcription quantitative polymerase chain reaction products were analyzed by Ct value and hybridized with probes for HPVs. Samples were analyzed for the presence of 19 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68a, 68b, 69, and 82) and 17 low-risk HPV types (6, 11, 30, 32, 40, 42, 43, 44, 54, 55, 62, 70, 72, 81, 84, 90, and 91).

1. Statistical analysis
-----------------------

Data were analyzed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL). Categorical variables were indicated as numbers and percentages. To assess the risk of cytological progression associated with HPV genotypes, relative risk (RR) with 95% confidence intervals (CI) was estimated by chi-square test. All p-values of less than 0.05 were considered statistically significant.

Results
=======

Among a total of 1,158 patients in the Korean HPV cohort study, 636 patients met the eligibility criteria of this study ([Fig. 1](#f1-crt-2016-013){ref-type="fig"}). ASC-US and LSIL were observed in 360 patients (56.6%) and 276 patients (43.4%), respectively. With respect to follow-up, 429 patients (67.5%) were followed up at 6 months and 301 (47.3%) at 12 months. The prevalence of high-risk HPV infections at the time of enrollment is summarized in [Table 1](#t1-crt-2016-013){ref-type="table"}. The most common type of high-risk HPV was type 16 (12.3%) as a single infection (n=85) and multiple infection (n=58). In this cohort, HPV 58 was the second most common type, with 74 patients having a single infection and 42 patients having multiple infections. Only ten patients with HPV 58 were co-infected with HPV 16 or 18. Among the ten most common high-risk HPVs, HPV 58, 56, 53, and 52 ranked as the top five. Cytological changes in patients with high-risk HPV infections other than HPV 16/18 during the follow-up periods are shown in [Table 2](#t2-crt-2016-013){ref-type="table"}. The rates of regression, no change, and progression of cervical cytology were 58.0%, 26.1%, and 15.9% at 6 months and 62.1%, 22.6%, and 15.3% at 12 months; 113 of 360 cases of ASC-US (31.4%) had regressed to normal cytology at 6 months; 136 of 276 cases of LSIL (49.3%) had regressed to either ASC-US (n=54) or normal cytology (n=82).

However, 147 of 301 (48.8%) ASC-US/LSIL cases maintained abnormal cytology for 12 months. In the unchanged and progression groups, the persistent rates of high-risk HPV infections other than HPV 16/18 were markedly higher than in the regression group (p \< 0.001). Among patients in the progression group, only three patients (4.4%) and one patient (2.2%) were HPV negative by HPV DNA test at 6 and 12 months, respectively. However, in the regression group, HPV infections had cleared in up to 62.6% of patients at the 12-month follow-up.

Analyses of high-risk HPV infections other than HPV 16/18 showed persistence in 41.9%, incidental infection in 24.6%, and clearance in 33.5% of patients at 12 months; 36.5% of the persistent infections were identified as having been caused by the same genotype on all HPV DNA tests. In addition, persistent infection with each HPV genotype showed a significant correlation with the prognosis of cervical cytology. The rates of persistent infection for other high-risk HPVs gradually increased from regression to progression in cytological prognosis (p \< 0.001).

With the exception of HPV 16/18, the HPV type-specific prognoses of cervical cytology are shown in [Table 3](#t3-crt-2016-013){ref-type="table"}. The cytological progression rates of HPV 58, 56, 53, 52, 39, 51, 68, and 66 single infections were 30.3%, 2.9%, 7.7%, 13.1%, 11.8%, 7.2%, 15.4%, and 5.9%, respectively, at 12 months. Except for HPV 58, low progression rates were observed for the other common HPV types (1.5%-29.3%) in both single and total infections. A relatively high progression rate (26.0%-37.5%) was observed for HPV 58 infection during the follow-up periods. The rate of cytological progression was 27.0% (27 out of 100) in the HPV 16 persistence group, and 9.8% (4 out of 41) in the HPV 18 persistence group at 6 months of follow-up.

According to the genotype and follow-up duration, the RRs to progression of cytology are shown in [Table 4](#t4-crt-2016-013){ref-type="table"}. HPV 58 single infection with ASC-US/LSIL resulted in a significantly higher risk of progression, compared with other common high-risk HPVs at 6 and 12 months (RR, 3.30; 95% CI, 2.04 to 5.30; p \< 0.001 and RR, 5.03; 95% CI, 2.56 to 9.91; p \< 0.001). Type 56, 53, and 52 HPVs, which initially ranked among the top five types, showed no significant RRs.

Discussion
==========

In this study, HPV 16 (12.3%) was clearly the predominant HPV type identified among the 1,158 women with ASC-US or LSIL, consistent with the universal trend among prevalent HPV types. However HPV 18 (6.0%) was not frequent in our study. Instead of HPV 18, HPV 58 (10.0%) was the second most common HPV type. This finding is consistent with those of other previous studies conducted in East Asia. The overall reported prevalence of HPV 58 was 11.4% in a study from Hong Kong \[[@b11-crt-2016-013]\]. In a study conducted in China, HPV 58 was more frequent than HPV 18 in precancerous lesions (19.1% vs. 5.4%, respectively) and the same infection rates for HPV 58 and HPV 18 were reported in cervical cancers (9.4% each) \[[@b12-crt-2016-013]\]. HPV 58 accounts for a considerable disease burden in East Asia. Its prevalence in cervical cancer is higher in Asia (5.6%) than in other parts of the world (3.3%) \[[@b13-crt-2016-013]\]. In a large scale Korean study (n=1,650), HPV 58 was the second most common HPV in LSIL (8.1%) and HSIL (15.7%) \[[@b14-crt-2016-013]\]. HSIL has also shown a relatively high prevalence (17.2%) of HPV 58 infection in East Asia \[[@b15-crt-2016-013]\].

The lifelong risk for HPV infection is greater than 70% in sexually active women \[[@b16-crt-2016-013]\]. Most HPV infections are spontaneously cleared within 1 to 2 years because of immunological mechanisms \[[@b17-crt-2016-013],[@b18-crt-2016-013]\]. In a previous study evaluating HPV infections in adolescents, infections were spontaneously cleared by 12 months in over 50% of infections caused by high-risk HPV types and two-thirds of infections caused by low-risk HPV types \[[@b19-crt-2016-013]\]. In this study, the overall clearance rate of high-risk HPV types other than HPV 16/18 at 12 months was 33.5%. HPV clearance was also higher in the cytological regression group than in the unchanged and progression groups. Overall, approximately 60% of patients showed regression on the subsequent follow-up Papanicolaou tests.

On the other hand, persistence of HPV infection was closely related to the prognosis of cervical cytology. Approximately 15% of patients showed cytological progression on every follow-up test. The progression group showed significantly higher rates of persistent infection with all other high-risk HPV types. Significant decreases in the rates of persistent infection were observed in the cytological regression, the unchanged, and progression groups, in order (p \< 0.001). The results of this study with respect to cervical pathogenesis confirm that persistent high-risk HPV infection induces cervical carcinogenesis. In most cases, the persistence of high-risk HPV infection is related to an increased risk of developing precancerous lesion or invasive carcinomas \[[@b20-crt-2016-013]\]. The persistence of high-risk HPV infection for 1 or 2 years strongly predicts a diagnosis of CIN 2+ in the subsequent years \[[@b21-crt-2016-013],[@b22-crt-2016-013]\]. Furthermore, high HPV viral load was significantly associated with lymphovascular space invasion and deep stromal invasion in cervical cancer \[[@b23-crt-2016-013]\].

In the analysis of type-specific prognoses, HPV 58 resulted in high rates of cytological progression at 6 and 12 months, compared with other high-risk types (RR, 3.30; 95% CI, 2.04 to 5.30; p \< 0.001 and RR, 5.03; 95% CI, 2.56 to 9.91; p \< 0.001). The reason for the high prevalence of HPV 58 and cervical carcinogenesis in East Asia is not fully understood, but may result from differences in the oncogenic potentials among the high-risk HPV types. Also, the oncogenicity of viral variants and host genetic backgrounds may play roles in the distinct geographical distribution of HPV 58. A multi-step process involving various host factors is needed for development of tumor cells from an HPV-infected epithelium \[[@b24-crt-2016-013]\]. The prevalence of HPV 58 increases significantly according to the severity of cervical neoplasia, and its variants are epidemiologically associated with a higher oncogenic risk \[[@b11-crt-2016-013]\]. Four featured variant lineages of HPV 58 (sublineage A1) showing a regional preponderance in Asia, and associated with a higher risk for cervical neoplasia, were recently reported \[[@b13-crt-2016-013],[@b25-crt-2016-013]\]. Therefore, the detection of HPV 58 in addition to HPVs 16 and 18 in cytologically abnormal women may provide an early indicator of cervical precancerous lesion and invasive cancers in East Asia. In addition, it may be helpful in predicting the effects of the next generation vaccines for other high-risk HPVs (non--HPV 16/18) \[[@b26-crt-2016-013]\].

This study was the first Korean HPV cohort study and provided a relatively large-scale assessment of the distribution of HPV types in South Korea. The results showed the impact of HPV genotypes on the natural course of cervical cytology over the course of 1 year. The evaluation of this cohort is ongoing and we will report follow-up data from the longitudinal study.

Conclusion
==========

Overall, HPV genotypes numbered in the 50s were frequent in Korean women with ASC-US and LSIL. In particular, HPV 58 was the most common high-risk HPV other than HPV 16/18 and greatly contributed to cytological progression in women with ASC-US/LSIL. This result may help us to understand the HPV genotype distribution and provide additional information on the association of HPV types other than HPV 16/18 with the prognosis of abnormal cytology.
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###### 

Prevalence of HPVs among women with ASCUS or LSIL

  Category    Rank   HPV genotype   No. (%) (n=1,158)
  ----------- ------ -------------- -------------------
  High risk   1      HPV 16         143 (12.3)
              2      HPV 58         116 (10.0)
              3      HPV 56         102 (8.8)
              4      HPV 53         97 (8.4)
              5      HPV 52         89 (7.7)
              6      HPV 39         72 (6.2)
              7      HPV 18         70 (6.0)
              8      HPV 51         66 (5.7)
              9      HPV 68         59 (5.1)
              10     HPV 66         53 (4.6)
              11     HPV 35         41 (3.5)
              12     HPV 33         37 (3.2)
              13     HPV 31         28 (2.4)
              14     HPV 59         24 (2.1)
              15     HPV 45         16 (1.4)
              16     HPV 67         6 (0.5)
              17     HPV 82         5 (0.4)
              18     HPV 69         4 (0.3)
  Low risk    1      HPV 70         41 (3.5)
              2      HPV 40         33 (2.8)
              3      HPV 54         28 (2.4)
              4      HPV 44         27 (2.3)
              5      HPV 62         23 (2.0)
              6      HPV 6          22 (1.9)
              7      HPV 81         20 (1.7)
              8      HPV 42         17 (1.5)
              9      HPV 30         16 (1.4)
              10     HPV 43         15 (1.3)
              11     HPV 11, 84     14 (1.2)
              12     HPV 90         11 (0.9)
              13     HPV 91         10 (0.9)
              14     HPV 55         4 (0.3)
              15     HPV 32, 72     1 (0.1)

Each type included single and multiple infection. HPV, human papillomavirus; ASC-US, atypical squamous cell uncertain significance; LSIL, low-grade squamous intraepithelial lesion.

###### 

Prevalence of high-risk HPVs infection according to the prognosis of cervical cytology

  Category              Regression   No change    Progression   Total        p-value
  --------------------- ------------ ------------ ------------- ------------ ----------
  **6 Mo**              249 (58.0)   112 (26.1)   68 (15.9)     429 (100)    \< 0.001
   High-risk HPV (+)    111 (44.6)   93 (83.0)    65 (95.6)     269 (62.7)   
   High-risk HPV (--)   138 (55.4)   19 (17.0)    3 (4.4)       160 (37.3)   
  **12 Mo**             187 (62.1)   68 (22.6)    46 (15.3)     301 (100)    \< 0.001
   High-risk HPV (+)    70 (37.4)    49 (72.1)    45 (97.8)     164 (54.5)   
   High-risk HPV (--)   117 (62.6)   19 (27.9)    1 (2.2)       137 (45.5)   

Values are presented as number (%). HPV, human papillomavirus.

###### 

HPV type-specific prognosis for cervical cytology

  HPV genotype   Prognosis of cytology   Single infection   Total infections               
  -------------- ----------------------- ------------------ ------------------ ----------- -----------
  HPV 58         Progression             18 (37.5)          10 (30.3)          22 (29.7)   13 (26.0)
                 No change               10 (20.8)          6 (18.2)           18 (24.3)   12 (24.0)
                 Regression              20 (41.7)          17 (51.5)          34 (46.0)   25 (50.0)
  HPV 56         Progression             1 (1.8)            1 (2.9)            1 (1.5)     2 (4.2)
                 No change               11 (20.0)          2 (5.9)            22 (33.3)   7 (14.6)
                 Regression              43 (78.2)          31 (91.2)          43 (65.2)   39 (81.2)
  HPV 53         Progression             3 (8.6)            2 (7.7)            6 (9.2)     4 (8.5)
                 No change               6 (17.1)           4 (15.4)           13 (20.0)   10 (21.3)
                 Regression              26 (74.3)          20 (76.9)          46 (70.8)   33 (70.2)
  HPV 52         Progression             6 (17.6)           3 (13.1)           11 (19.3)   12 (29.3)
                 No change               11 (32.4)          5 (21.7)           18 (31.6)   9 (21.9)
                 Regression              17 (50.0)          15 (65.2)          28 (49.1)   20 (48.8)
  HPV 39         Progression             3 (11.5)           2 (11.8)           5 (11.4)    3 (10.7)
                 No change               7 (26.9)           5 (29.4)           13 (29.5)   10 (35.7)
                 Regression              16 (61.6)          10 (58.8)          26 (59.1)   15 (53.6)
  HPV 51         Progression             2 (9.1)            1 (7.2)            5 (11.9)    5 (20.8)
                 No change               5 (22.7)           3 (21.4)           14 (33.3)   5 (20.8)
                 Regression              15 (68.2)          10 (71.4)          23 (54.8)   14 (58.4)
  HPV 68         Progression             4 (23.5)           2 (15.4)           8 (25.0)    5 (22.7)
                 No change               4 (23.5)           3 (23.1)           9 (28.1)    5 (22.7)
                 Regression              9 (53.0)           8 (61.5)           15 (46.9)   12 (54.6)
  HPV 66         Progression             3 (13.6)           1 (5.9)            4 (11.4)    2 (8.0)
                 No change               6 (27.3)           5 (29.4)           11 (31.4)   7 (28.0)
                 Regression              13 (59.1)          11 (64.7)          20 (57.2)   16 (64.0)

Values are presented as number (%). HPV, human papillomavirus.

###### 

HPV type.specific relative risk to progression of cervical cytology

  HPV type   6 Mo     12 Mo                                                     
  ---------- -------- ------------------ ---------- -------- ------------------ ----------
  HPV 58     18/48    3.3 (2.04-5.30)    \< 0.001   10/24    5.03 (2.56-9.91)   \< 0.001
  Others     22/211   1                             12/153   1                  
  HPV 56     1/55     0.10 (0.14-0.72)   \< 0.001   1/14     0.52 (0.07-4.18)   0.458
  Others     39/204   1                             22/163   1                  
  HPV 53     3/35     0.51 (0.17-1.60)   0.170      2/15     1.08 (0.26-4.49)   0.583
  Others     37/224   1                             20/162   1                  
  HPV 52     6/33     1.22 (0.54-2.76)   0.401      2/18     0.88 (0.22-3.57)   0.607
  Others     34/226   1                             20/159   1                  
  HPV 39     3/26     0.71 (0.23-2.27)   0.404      2/10     1.76 (0.40-7.77)   0.360
  Others     37/233   1                             20/167   1                  
  HPV 51     2/22     0.55 (0.13-2.25)   0.306      1/12     0.64 (0.09-4.72)   0.545
  Others     38/237   1                             21/165   1                  
  HPV 68     4/17     1.69 (0.58-4.90)   0.257      2/10     1.76 (0.40-7.77)   0.360
  Others     36/242   1                             20/167   1                  
  HPV 66     3/22     0.86 (0.27-2.80)   0.549      1/28     0.26 (0.04-1.83)   0.100
  Others     37/237   1                             21/149   1                  

HPV, human papillomavirus; RR, relative risk; CI, confidence interval.
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